Table 3

De novo inhibitors occurring in previously treated patients who switched FVIII product in the frame of the Canadian surveillance system

Giles et al49Rubinger et al50
339 inhibitor-free patients185 inhibitor-free patients
All switched from plasma-derived to a recombinant FVIII productAll switched from a recombinant FVIII to another second-generation recombinant FVIII
Central testing every 12 moCentral testing every 12 mo
2 y of follow-up2 y of follow-up
Inhibitor incidence: 14.7 per 1000 person-yearsNo de novo inhibitor